×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DNLI – denali therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DNLI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/2
08:02 pm
dnli
Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Medium
Report
Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/2
08:03 am
dnli
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.
2/26
04:22 pm
dnli
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
2/26
04:01 pm
dnli
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Low
Report
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2/23
06:01 pm
dnli
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
2/19
08:30 am
dnli
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Medium
Report
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
2/6
08:04 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
Medium
Report
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
2/5
02:00 pm
dnli
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
Low
Report
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/26
04:16 pm
dnli
Form 10-K Denali Therapeutics Inc. For: Dec 31
Low
Report
Form 10-K Denali Therapeutics Inc. For: Dec 31
2/26
04:13 pm
dnli
Form S-8 Denali Therapeutics Inc.
Low
Report
Form S-8 Denali Therapeutics Inc.
2/26
04:10 pm
dnli
Form 8-K Denali Therapeutics Inc. For: Feb 26
Low
Report
Form 8-K Denali Therapeutics Inc. For: Feb 26
2/5
04:14 pm
dnli
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Medium
Report
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
2/4
04:17 pm
dnli
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Medium
Report
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
2/3
04:47 pm
dnli
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Low
Report
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
1/8
04:20 pm
dnli
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Schuth Alexander O.
Low
Report
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Schuth Alexander O.
1/8
04:20 pm
dnli
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Watts Ryan J.
Low
Report
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Watts Ryan J.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/14
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
29.4%
1/26 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "buy" rating. 13.7%
4/1 Form 4/A Denali Therapeutics Inc. For: Feb 08 Filed by: Watts Ryan J. 8.9%
3/13 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Evercore ISI to an "outperform" rating. 7.9%
7/2 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $23.00 price target on the stock. 6.2%
10/21 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.7%
1/30 Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% [Yahoo! Finance News] 5.3%
12/3 30 Under 30 2020: Meet The Sports World’s Brightest Young Stars [Forbes] 4.6%
6/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 4.5%
11/26 Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O. 4.5%
1/26 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "buy" rating. 13.7%
4/1 Form 4/A Denali Therapeutics Inc. For: Feb 08 Filed by: Watts Ryan J. 8.9%
3/13 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Evercore ISI to an "outperform" rating. 7.9%
7/2 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $23.00 price target on the stock. 6.2%
10/21 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.7%
1/30 Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% [Yahoo! Finance News] 5.3%
12/3 30 Under 30 2020: Meet The Sports World’s Brightest Young Stars [Forbes] 4.6%
6/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 4.5%
11/26 Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O. 4.5%
TOP News Decliners
2/26
Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.
-12.1%
3/30 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. -11.1%
1/27 Denali Therapeutics Announces Proposed Offering of Common Stock -10.0%
1/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -9.3%
9/25 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Wedbush. They set a "neutral" rating on the stock. -9.1%
2/24 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $35.00 price target on the stock. -7.2%
5/10 Form 4/A Denali Therapeutics Inc. For: Apr 01 Filed by: Ho Carole -6.7%
1/29 Form 424B5 Denali Therapeutics Inc. -6.5%
3/12 Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer -6.2%
9/13 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Nomura. They set a "buy" rating on the stock. -5.9%
3/30 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. -11.1%
1/27 Denali Therapeutics Announces Proposed Offering of Common Stock -10.0%
1/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -9.3%
9/25 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Wedbush. They set a "neutral" rating on the stock. -9.1%
2/24 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $35.00 price target on the stock. -7.2%
5/10 Form 4/A Denali Therapeutics Inc. For: Apr 01 Filed by: Ho Carole -6.7%
1/29 Form 424B5 Denali Therapeutics Inc. -6.5%
3/12 Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer -6.2%
9/13 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Nomura. They set a "buy" rating on the stock. -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: